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SH3-domain Binding Glutamic acid Rich Like 3 (SH3BGRL3) belongs to the 
SH3BGR family, it is ubiquitously expressed and encodes for a 93 AA 
thioredoxin-like evolutionary conserved protein. Its altered expression and 
tumor promoting role were described in certain malignancies e.g. lung, 
papillary and urothelial cancer. SH3BGRL3 shows a significant homology with 
Escherichia coli Glutaredoxin 3 however it is devoid of potential redox 
enzymatic activity, lacking the enzymatic site. This suggests some possible 
role as a modulator of GRXs activities or other proteins (e.g. its potential 
binding to Grb2 adaptor or EGFR proteins was emphasized in certain cell 
lines). 
 
Our previous co-immunoprecipitation experiments demonstrated that 
SH3BGRL3 (and SH3BGRL as well) is able to interact Myo1c (via IQ domains) 
motor protein in SKBR3 cell line. Here we investigated the involvement of Ca2+ 
on the condition of this binding through pull-down experiments in SKBR3 cell 
lysates, the localization of the SH3BGRL3/Myo1c complex in MDA-MB-231 
model and further functional role of SH3BGRL3 protein in correlation with 
tumor cell growth, survival and metastatic behavior were studied. Co-IP, pull-
down, genetic modification (over-expressing and silencing) experiments, 
cellular localization studies, Western blots analysis, migration and invasion 
assays, metabolic analysis and tamoxifen sensitivity assays were performed 
in selected breast cancer cell lines (SKBR3, MDA-MB-231 and MCF-7) in 
order to investigate the functional role of the SH3BGRL3 protein. 
 
In this work, the Ca2+ dependence of SH3BGRL3/Myo1c interaction 
were highlighted in SKBR3. The SH3BGRL3/Myo1c complex formation was 
also investigated in the highly invasive MDA-MB-231 cell line. However, such 
ability to complex formation of SH3BGRL/Myo1c could not be detected in this 
cell line, differently from what we sound in SKBR3 model. Moreover, our 
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results could not confirm that SH3BGRL3 (or SH3BGRL) interact with ErbB2, 
EFGR or Grb2 protein adaptor. In addition, the SH3BGRL3/Myo1c/actin 
complex formation and the role of SH3BGRL3 in cell motility, migration and 
invasion were shown in the MDA-MB-231 cell line. This motility regulatory 
function was SH3BGRL3 protein specific in our model, e. g. the other member 
of the protein family SH3BGR (e.g. SH3BGRL) had no such effect and was not 
able to co-immunoprecipitate with Myo1c. It was an interesting observation 
that Myo1c is detectable in exosomes isolated from MDA-MB-231 suggesting 
this protein as a potentially useful exosomes marker. 
 
The specific tumorigenic roles of the SH3BGRL3 protein were further 
confirmed using SH3BGRL3 negative MCF-7 cell line in our experiments. 
Decreased ERα, increased motility and metabolic alterations (elevated 
mitochondria oxidation and glycolytic function) were detected in case of 
SH3BGRL3 over-expression in genetically modified MCF-7 cells. In parallel 
with these, 4’OH-TAM sensitivity was reduced in vitro compared to control 
MCF-7. 
 
Based on these findings, SH3BGRL3 protein expression could 
influence cell motility, cell invasiveness and it could be involved in resistance 





The completion of the "human genome" project in the early 2000s led to the 
identification of all human genes and the grouping of many of them into gene 
families based on significant homologies in the amino acid sequence. Over a 
decade later, however, the functional role of a substantial number of genes 
and genetic families remains in part or completely to be defined. 
 
 
The SH3BGR gene 
The SH3BGR gene (SH3 domain Binding Glutamic acid Rich) was identified 
and characterized during a project that had as its objective the construction of 
a transcriptional map of the region of chromosome 21 involved in the 
pathogenesis of congenital cardiopathies characteristic of Down Syndrome 
[1,2] . During the early stages of the embryonic development of the mouse, 
SH3BGR is selectively expressed in the heart while in later stages the 
expression appears extended to the striated musculature and to the smooth 
muscles of some organs such as the urinary bladder [3]. 
SH3BGR encodes for a mostly cytosolic protein of 174 amino acids 
characterized by a high conserved N-terminal domain and a C-terminal domain 
enriched in glutamic acid residues. Within the N-terminal domain there is a 
sequence enriched in proline (PLPPGIF) which contains a potential binding 
motif for the SH3 domain (consensus sequence: PXXP) [4] and one for the 
specific EVH1 domain of the Homer proteins [5]. 
SH3BGR effect on the cardiac morphogenesis process has been studied in a 
mouse model in which the SH3BGR gene expression in the heart has been 
increased to levels similar to those found in human trisomy 21. That study did 
not find the presence of cardiac malformations correlating the entire 
expression portrait of SH3BGR [2]. A study conducted recently on Xenopus 
leavis has shown that the extinction of SH3BGR expression influenced the 
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alterations in the development of sarcomeres and in the formation of the heart 
[6]. 
Since the C-terminal domain has an α-helix conformation, it seems to be able 
to bind calcium in a similar way to calsequestrin (in the endoplasmic reticulum) 
[7], through the high content of glutamic acid residues [1]. The domain for the 
binding of SH3, in the proline-rich region, is a very conserved sequence 
important for protein-protein interaction and for signal transduction processes. 
The understanding of the correct intracellular localization of the protein 
encoded by the SH3BGR gene and the identification of the proteins that 
interact with it remains a field of investigation still open, but that could provide 
important data on its function and on the correlation between a hyper-
expression of this protein and the development of congenital cardiac diseases 
that characterize many subjects with Down Syndrome [8]. 
Following the characterization of the SH3BGR gene [9], three new genes have 
been identified that encode for small proteins called SH3BGRL [10], 
SH3BGRL2 [11] and SH3BGRL3 [12], which show a high homology with the 
N-terminal region of SH3BGR but lack the C-terminal region (Figure 1). The 
subsequent identification and characterization of SH3BGR-like genes [12] 
defined a new genes family coding for small proteins belonging to the 
Thioredoxin (Trx) superfamily, but lacking the CXXC sequence that 





Figure 1. Human SH3BGR family proteins amino acids sequence alignment. The homology 
among the four protein is high, especially at the N-terminal domain. SH3BGR, SH3BGRL and 
SH3BGRL2 are considerably conserved, while SH3BGRL3 shows some differences in the 
amino acid sequence. SH3BGR has a long C-terminal domain that lacks in the other SH3BGR 
family members. The SH3- binding domain is boxed in red and the Homer EVH1- binding 
domain boxed is in green. Identical amino acids are shaded in dark grey while conservative 
substitutions are in light grey. 
 
 
The SH3BGRL gene 
The SH3BGRL (SH3BGR Like) gene is located on the X chromosome, in the 
q13.3 region. SH3BGRL is expressed ubiquitously, not only in muscle tissue 
such as SH3BGR, and encodes for a cytoplasmatic protein of 114 amino acids 
(smaller than that encoded by SH3BGR) that preserves the region rich in 
proline containing the binding regions for the SH3 and the EVH1 domains [10]. 
Indeed, SH3BGRL shares a 60% identity of amino acids and 84% of amino 
acid convervation level with the N-terminal region of SH3BGR protein. The N-
terminal of SH3BGRL also appears to be highly conserved, sharing 95% 
identity with the mouse homologue protein(Figure 2). Majid and co-workers 
[13] have demonstrated that the suppression of SH3BGRL gene plays an 
important role in the neoplastic transformation induced by the oncogene v-rel 
in lymphatic cells and in chicken fibroblasts. Restoring the normal expression 
of SH3BGRL reduces the transforming capacity of v-rel by 76%. In mice, 
SH3BGRL (mSH3BGRL) seems to play a role in cell invasion in vitro and tumor 
metastasis through its binding with c-Src oncogene promoting its activation 
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though human SH3BGRL (hSH3BGRL) shows a tumour suppressor activity 
[14]. 
Moreover, Muniz Lino and collaborators [15] identified SH3BGRL among the 
sixteen proteins whose expression is most increased in samples of triple 
negative breast cancer, characterized by poor response to therapies and high 
invasive capacity. 
Quantitative changes in the SH3BGRL expression have also been described 
in neurodegenerative disorders: in a study of the cells belonging to the 
substantia nigra in subjects with Parkinson's disease, Werner and colleagues 
identified SH3BGRL among the proteins which expression is significantly 
increased in diseased cells [16]. An increased expression of SH3BGRL has 
also been described in brain tissue of patients with Alzheimer's disease and 
fibroblasts from subjects with presenilin mutations 1 [17]. 
 
Figure 2. SH3BGRL protein sequence alignment. SH3BGRL shows high homology among 
different species. Dots represents identical amino acids. SH3BGRL from Mus musculus 
(mSH3BGRL) and Homo sapiens SH3BGRL (hSH3BGRL) show a high identity though Wang 




The SH3BGRL2 gene 
The SH3BGRL2 (SH3BGR Like 2) gene is located on chromosome 6 in the 
q13-15 region, it encodes a protein of 107 amino acids which, like the 
SH3BGRL protein, it shows a high homology with the N-terminal region of 
SH3BGR and it is very similar to the glutaredoxin present in E. coli.  
SH3BGRL2 shows 63% identity and 83% similarity with the N-terminal region 
of SH3BGR; 63% identity and 79% similarity with SH3BGRL, and 39% identity 
and 60% similarity with SH3BGRL3. Like SH3BGRL and SH3BGRL3, the 
SH3BGRL2 protein also lacks the C-terminal sequence rich in glutamic acid 
[10]. 
SH3BGRL2 gene generates transcripts of approximately 3 and 5 kb, 
characterized by a particularly extensive and untranslated 3 ’regions rich in 
AUUUA repetitions (AU Rich Elements, AUREs) that are related to the rapid 
degradation of messenger RNA [17]. The tissue distribution of SH3BGRL2 
expression was seen to be abundant in the brain, placenta, liver and kidney. 
An interesting aspect of SH3BGRL2 is its expression in the retina, an 
expression that is elevated in the fovea. A molecular analysis on differential 
expression in cones and rods has shown that SH3BGRL2 transcripts are 
present exclusively in cones. The peculiar expression and chromosomal 
localization makes SH3BGRL2 a potential candidate for the pathogenesis of 
familial forms of retinal degeneration [18]. 
Regarding the cellular localization of the SH3BGRL2 protein, positive signals 
have emerged from the nucleus and from the perinuclear region. 
Recently, SH3BGRL2 protein has been found as a tumor suppressor and 
modulator of cell growth and metastasis in clear cell renal carcinoma via 






The SH3BGRL3 gene 
The SH3BGRL3 (SH3BGR Like 3) gene is mapped to chromosome 1p34.3-
35. SH3BGRL3 encodes for a small protein of 93 amino acids, ubiquitously 
expressed, characterized by a high degree of evolutionary conservation [12]. 
Compared to the other SH3BGR members family, SH3BGRL3 protein shows 
slight differences: 39% identity and 76% similarity to the N-terminal SH3BGR 
protein region; 42% identity and 73% similarity to the SH3BGRL protein. 
The most important aspect that differentiates SH3BGRL3 from other proteins 
in the family is the modification of the proline-rich sequence with the 
consequent loss of potential binding sites for the SH3 and EVH1 domains. 
The analysis of the amino acid sequence shows a significant homology with 
the Escherichia coli glutaredoxin 3; however SH3BGRL3 is completely devoid 
of the CXXC sequence which is present in all glutaredoxin proteins and 
constitutes the active enzymatic site. SH3BGRL3 is therefore devoided of 
potential redox enzymatic activity. The structure of SH3BGRL3 was solved by 
crystallization [20] and NMR [21] techniques. 
 
Glutaredoxins (GRXs) are ubiquitous GSH-dependent oxidoreductases that 
provide the regulation of cellular process associated with changes in the redox 
state [21]. Structurally, GRXs belong to the TRx superfamily and the common 
domain consists of a four stranded ß-sheet surrounded by three α-helices and 
all oxidoreductase proteins share a similar active site motif (Cys-X-X-Cys or 
Cys-X-X-Ser) located between ß-sheet 1 and α-helix 1. As GRXs, also 
SH3BGRL3 presents the same domain formed by four stranded ß-sheet 
surrounded by three α-helices.  
The SH3BGRL3 protein is characterized by a carboxyl-terminal half of about 
60 amino acids, that shows significant sequence identity (21–33%) with the 
corresponding regions of Escherichia coli GRX1 and GRX3, and with human 
and pig liver GRXs (Figure 3). On the contrary, the N-terminal sequence of 
SH3BGRL3 differs from those of E. coli and mammalian GRXs, lacking both 
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Cys residues essential for the enzymatic activity in GRXs. Indeed, SH3BGRL3 
is devoid of redox enzymatic activity and this suggests a possible role of the 
SH3BGRL3 protein as a modulator of GRXs activities by competitive binding 
to target proteins [21]. 
 
 
Figure 3. Amino acids sequence alignment of the SH3BGRL3 protein with E. coli GRX1, E. 
coli GRX2, Human GRX and Pig liver GRX proteins. Residues assuming ß-sheet and α-helix 
conformations are in blue and pink, respectively. The GRX residues of the catalytic CXXC 
motive are boxed in red. 
 
 
Modifications of SH3BGRL3 expression have been related to the invasive 
capacity of different tumour forms. Recently, SH3BGRL3 has been identified 
among the markers of negative prognosis in lung adenocarcinoma [23], 
papillary thyroid cancer [24] and in the secretome from osteoblasts derived 
from sclerotic subchondral bone in osteoarthritis [25] suggesting SH3BGRL3 
to be a secreted protein as a potential prognostic biomarker of these types of 
tumor. 
Chiang et al [26] have shown that an increase of SH3BGRL3 expression 
correlates with an increased invasive capacity in uro-epithelial carcinoma, 
associating its expression with epithelial-mesenchymal transition (EMT), cell 
migration, cell proliferation and an increased risk of tumor progression in 
patients with non-invasive cancer. They found that the SH3BGRL3 protein 
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interacts with Epidermal Growth Factor Receptor (EGFR) at Y1068, Y1086 and 
Y1172 trough Grb2 adaptor protein. The interaction between Grb2 and 
SH3BGRL3 is hypothesized to occur through SH3BGRL3 proline-rich motif 
even although SH3BGRL3 does not have a canonical SH3-binding domain 
[12]. 
Interesting is the identification of SH3BGRL3 mRNA at the level of membrane 
protrusions related to the invasion process in the breast cancer line MDA-MB-
231 [28].  
As with SH3BGRL, expression levels of the SH3BGRL3 protein were also 
found to be increased in fibroblasts from patients with familial Alzheimer's 
disease due to Presenilin-1 mutations [18]. 
SH3BGRL3 results to be very conserved along many species including those 
far from humans, like Xenopus Laevis and Danio rerio (Figure 4) suggesting 
a possible common and important role of the SH3BGRL3 protein in the biology 
of these organisms. 
 
 
Figure 4. The SH3BGRL3 protein sequence alignment. SH3BGRL3 shows high homology in 







Myosins belong to a big family of ATP-dependent motor proteins associated 
to the cytoskeleton and able to “move” along actin filaments, typically from the 
minus end of them (depolymerisation) to the plus end (polymerization), except 
for myosin IV which progresses from the plus end to the minus end [29]. 
They are usually huge proteins that can act as homodimers (e.g. myosin II) or 
they can form a complex with other proteins. They mediate many cell functions, 
from cell movement and muscle contraction to the translocation of vesicles 
along the cytoskeleton and cell membrane remodelling (e.g. endocytosis and 
exocytosis, lamellipodia and pseudopodia formation), all of them driven by 
hydrolyzing ATP to ADP and moving along actin filaments [30]. 
The myosin family counts at least 35 distinct groups but they share a common 
structure. This structure is made by: 
i) a catalytic motor domain (“head”) at the N-terminal. This globular domain 
has two important binding sites: one is the region that contacts the actin and 
the other one is the ATP motif that can hydrolyze ATP in ADP+Pi, generating 
the mechanical force necessary to change its conformation and slide along the 
actin filaments; ii) a central region (“neck”) that acts as a linker and as a lever 
arm allowing the motor domain to spread the force generated by the ATP 
hydrolysis to the tail. The neck is made by a repetition of IQ domains [31] and 
it is often associated to calmodulin (CALcium-Modulated protein, CaM) [32] or 
other light chains proteins (called Light Chain-Binding Domain) that can bind 
myosins or build a macromolecular complex with a regulatory function; iii) a C-
terminal domain (“tail”) that contains specific domains able to bind vesicles, 
cell membranes (via lipids) even other myosins proteins. The ability of this 
region to bind different molecules depend on the specific kind of myosin. 
 
The best known member of the family, and the first to be described, is the 
myosin II (defined a “conventional myosin), whose function is carried in 
muscular cells. Subsequently, other myosins have been characterized as 
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Myosin 1C (Myo1c) belongs to the class 1 myosins. They are all single chain 
molecules, most of them are ubiquitously expressed (1B, 1C, 1D and 1E) and 
others are tissue specific (e.g. 1A is expressed in the gut, while 1E and 1F are 
expressed in the hematopoietic cells). Eight different subtypes have been 
described (Figure 5) and each of them contains the motor domain at the N-
terminal, the “neck region” consisting of several IQ calmodulin-binding motifs 
and the “tail region” at the C-terminal. In all of them the “tail region” contains a 
Tail Homology 1 (TH1) domain, followed by a Pleckstrin Homology (PH) 
domain able to bind membrane lipids (as phosphatidylinositol 4 5-
bisphosphate, PIP2). In addition, the long tail of myosin 1E and myosin 1F 
contains also a TH2 domain and a C-terminal SH3 domain as shown in the 
figure below. As “conventional myosins”, all class 1 myosins are also able to 
bind the actin cytoskeleton [34]. 
 
 
Figure 5. Schematic representation of class I Myosins. All the members are single chain 
molecules having a N-terminal domain (“head”, light red) able to bind actin cytoskeleton, 
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different IQ domains (orange) able to bind CaM or other Light Chain-Binding Domain and a C-
terminal domain (“tail”). The tail is made by a TH1 domain (light green) and a PH domain 
(purple). Some of these myosins present also two additional domains: a TH2 domain (light 
blue) and a SH3 domain (yellow). 
 
 
Myosin 1C (encoded by Myo-1c gene localized on chromosome 17p13.3) is a 
1063 amino acids protein initially described as a nuclear myosin. Myo1c 
shares a common structure with all others myosins (Figure 6): the N-terminal 
“head region” is 700 amino acids long, the “neck region” 90 amino acids and 
C-terminal “tail region” about 270 amino acids long. The “tail region” is made 
by three IQ domains (named IQ1, IQ2 and IQ3) followed by a post-IQ region 
made by three α-helices (named α2, α3 and α4) [35]. IQ domains are basic, 
often amphipatic α-helices consisting of approximately 20 amino acids. For 
myosins, the IQ motif consensus sequence is IQXXXRGXXXR [36]. Myo1c 1Q 
region binds CaM, calmodulin-like proteins with EF-domain (e.g. Calcium-
Binding Protein 1, CaBP1 and Calcium- and integrin-binding-protein1, CIB1) 
and others light chain-binding proteins (LCBD) [37].  
CaM binds Myo1c IQ domains in presence of a low concentration of Ca2+ 
determining an increase of the stability in myosin 1c “neck region”, essential 
during the coup de force to transduce the tension generated by motor domain 
to the “tail region”. When Ca2+ concentration in the cell rises, CaM dissociates 
from IQ domains (binding Ca2+ through its EF-hand domains) and determines 
more flexibility of the Myo1c “neck region” [38]. 
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Figure 6. Myo1c Schematic representation. The “head region” (light red) binds ATP and actin 
while “tail region” (green) binds cell membrane through its PH domain (purple). The “neck 
region” is made by three IQ domains (orange) followed by a post IQ region (alpha-helices, 
yellow). According to recent papers, two CaM molecules interact with IQ domain 1 (partially 
also with the “head region” and 2; the third one with IQ3 domain, α2, α3 and partially α4 region. 
 
 
Myo1c is expressed in most eukaryotic cells and it has been co-localized with 
actin-rich cell periphery along the plasma membrane. According to this, Myo1c 
results important in the communication between the inside of the cell and its 
environment transducing signals from cell membrane receptors to the 
cytoskeleton, exposing ionic channels on the plasma membrane in response 
to different stimuli, transporting vesicles from and to the plasma membrane 
and helping their release into the outside environment [39, 40, 41]. 
Myo1c shows also lots of specific functions in different specialized cell type. In 
the sensory hair cells of the inner ear, Myo1c is expressed in the stereocilia 
tips where it controls the tension of the tip links that connect neighboring 
stereocilia during the hair cell adaptation [42, 43, 44]. 
Myo1c facilitates the correct targeting of lots different cargoes from the 
cytoplasm to the plasma membrane, for examples Myo1c has been implicated 
in insulin-stimulated glucose transport 4 (GLUT4) trafficking and plasma 
membrane fusion via interaction with ReIA in adipocytes cell types [45, 46, 47]. 
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Otherwise, Myo1c stabilizes actin at the Golgi complex, facilitating the arrival 
of incoming transport carriers at the Golgi in human cells [48]. Myo1c plays an 
important role in membrane remodelling, through membrane uptake 
(endocytosis) and balanced exocytosis of intracellular membranes [49], in lipid 
raft recycling [50], in autophagosome/lysosome formation and in pathogen 
internalization (e.g. Salmonella) [51]. Myo1c localizes at the growing 
membrane protrusions generated during B cells spreading and it is actively 
recruited to the immune synapse, showing co-localization with MCH-II [52]. 
Myo1c shows also an important role in the development of the grown cone of 
neurons axons and dendrites where Myo1c localizes in lamellipodia and 
filopodia [53]. Myo1c is also critical in the formation of lamellipodia and cell 
migration in the model of N1 glioblastoma [54]. All this data suggest Myo1c as 
a molecular motor universally involved in membrane trafficking, cargo delivery 






























In 2005, Schulze at al. [56] published a proteomic work in which it was 
described the interaction patterns to all cytosolic phosphorylated tyrosine 
residues of all EGF-Receptor (Epidermal Growth Factor Receptor, or ErbB-
receptors) family members. In this study, SH3BGRL (or SH3BGRL3, since the 
paper refers to SH3BGRL, while the Protein Data Bank number indicated in 
paper points to the SH3BGRL3 protein) has been founded to bind 
phosphorylated Y891 in ErbB1 (EGFR) and phosphorylated Y923 and 
phosphorylated Y1196 in ErbB2. According to this, we investigated the 
SH3BGRL and SH3BGRL3 role in EGFR signal transduction using the SKBR3 
cell line, a breast cancer cell line over-expressing ErbB2 protein. After, Chiang 
et colleagues [13] revealed SH3BGRL3 able to interact directly with EGFR 
protein. 
It is well known that members of the ErbB-receptors, that are ubiquitously 
expressed, play a crucial role in cell proliferation and differentiation. In 
particular, changes in expression and aberrant activation, especially for EGFR 
and ErbB2, are related to a variety types of breast cancer development and 
progression including metastasis [57, 58]. 
According to this data, we were interested to investigate better the role of 
SH3BGRL and SH3BGRL3 proteins in the EGFR signal pathway. 
Since notwithstanding several by co-immunoprecipitations experiments no 
interaction between SH3BGRL (or SH3BGRL3) and the ErbB2 receptor could 
be demonstrated, we decided to analyse the co-immunoprecipitate of 
SH3BGRL3 in SKBR3 cell lysate by mass spectrometry analysis to identify 
any possible interactors. Mass spectrometry analysis of bands obtained by co-
immunoprecipitation of FLAG tagged SH3BGRL3 protein [59], as we already 
demonstrated, revealed the proteins Myosin 1c, Adseverin and Actin as 
possible SH3BGRL3 binders. Our result from the co-immunoprecipitation 
reflects the common role of Myosin 1c, Actin and Adseverin proteins have in 
the turn-over of the Actin Cytoskeleton [60]. We focused our attention on 
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Myosin 1c and the mass spectrometry result was confirmed by co-
immunoprecipitation assays in SK-BR-3 (previously transfected by FLAG-
SH3BGRL3 as a bait).  
After the demonstration of the SH3BGRL3 interaction with Myosin 1c, we 
investigated which part of Myosin 1c interacts with SH3BGRL3 protein and we 
demonstrated that essentially the “neck” region of Myosin 1c, composed by 
the IQ domains, is involved in this binding, suggesting SH3BGRL3 as a protein 
modulator of this region (like Calmodulin protein) [59, 61, 62]. 
In this study, we explore the binding conditions of SH3BGRL3 with the Myosin 
1c and we propose a possible function of the SH3BGRL3 protein in cancer 
progression, exploring and analysing its expression in different type of breast 
cancer cell lines. 
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MATERIAL AND METHODS 
 
Cell lines culture 
Human breast cancer cells line SKBR3, MDA-MB-231, MDA-MB-468, MCF-7, 
T47D and BT-474 (American Type Culture Collection, ATCC) have been 
maintained in DMEM (Euroclone) containing 10% FBS (Life Technology, 
ThermoFisher), 1% L-Glutamine (Life Technology, ThermoFisher) and 1 
mg/mL penicillin/streptomycin (Sigma) in 5% CO2 humidified atmosphere 
(receptor status is shown in Figure 7). For exosomes isolation, the MDA-MB-
231 cell line has been maintained in DMEM (Euroclone) containing 1% L-
Glutamine (Life Technology, ThermoFisher) and 1 mg/mL 
penicillin/streptomycin (Sigma) in 5% CO2 humidified atmosphere. 
 
Cell line Phenotype ER PR HER2 
SKBR3 Luminal HER2 - - + 
MDA-MB-231 Tripl negative - - - 
MDA-MB-468 Tripl negative - - - 
MCF-7 Luminal  + + - 
T47D Luminal  + + + 
BT-474 Luminal  + + + 
 
Figure 7. Receptor status (for Estrogen Receptor, ER; Progesteron Receptor, PR; and ErbB2, 









Constructs were built using In-fusion Cloning Kit (Clontech). We first amplified 
the DNA using Phusion Hot Start Flex DNA Polymerase (New England 
Biolabs) and a three-step PCR. Infusion Cloning Primers were designed 
including 15bp homologous to the ends of the linearized target vector. After 
PCR products running on agarose gel, we purified the sample using Exosap 
(Affimetrix). The recombination between the PCR product and the vector was 
performed using Infusion enzyme mix following the manufacturer’s protocol. 
We used pFLAG-CMV and pIRESpuro for eukaryotic expression, while pGEX-
6P-1 and pQE-30 are used for bacterial expression. For construct 
amplification, we transformed Stellar Competent Cells (Clontech) with Infusion 
products. Bacteria were grown in LB or in LB+Agar plates, both added with 
Ampicillin, at 37oC. The screening of positive colonies was performed using 
DNA amplification; positive colonies were amplified and plasmids were 
extracted using Plasmid Miniprep kit (Machery & Nagel). A couple of plasmid 
for each construct was sequenced using the BigDye Sequencing kit (Thermo 
Fisher Scientific) to detect if there were any mutations. Selected clones were 




SKBR3 and MDA-MB-231 cell lines were transiently transfected, at 70-90% of 
confluence, with the different constructs using Lipofectamine 2000 (Life 
Technology, Thermo Fisher) according to the manufacturer’s protocol. 
SH3BGRL and SH3BGRL3 silencing in MDA-MB-231 was performed using 
specific siRNA against SH3BGRL and SH3BGRL3 genes (Ambion) while a 
scrambled siRNA (Ambion) was used as negative control. 
To obtain a stable transfected cell line, the MCF-7 cell line was transfected 
using the Lenti-PacTM HIV Expression Packaging kit (GeneCopoeiaTM). 
Following the manufacturer’s protocol, we first produced the virus using 293Ta 
lentiviral packaging cells (GeneCopoeiaTM) and then we transfected target 
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cells with pReceveir-Lv105-SH3BGRL3 and pReceveir-LV105 alone as a 
negative control. Selection of transfected cells has been done using puromycin 
antibiotic (Gibco,Thermo Fisher). 
 
Cell lysis and Western blot 
Cells were washed with PBS (Gibco, Thermo Fisher) and lysed, using a 
scraper, in EB buffer (Hepes 20mM, NaCl 150mM, glycerol 10%, Triton X-100 
1%) or RIPA buffer (Sigma) added with Protease Inhibitors Cocktail (Sigma). 
Lysates were normalized on the basis of the total protein amount measured by 
Bradford assay (Biorad). Samples were run in SDS-PAGE on Mini-Protean 
TGX Precast Protein Gels (Biorad) using Colorbust Electrophoresis Marker 
(Sigma-Aldrich) and Leammli reducing buffer (Biorad). After electrophoresis, 
proteins were transferred on Hybond ECL Nitrocellulose Membrane (GE 
Healthcare) by Western blot technique. As primary antibodies, we used: α-
SH3BGRL 1:1000 (Santa Cruz), α-SH3BGRL3 1:500 (Sigma-Aldrich), α-
Myo1c 1:500 (Sigma-Aldrich), α-FLAG 1:1000(Sigma-Aldrich), α-GAPDH 
1:5000 (Abcam), α-halix 1:200 (Santa Cruz), α-Tom20 1: 250 (Santa Cruz), α-
ERα 1:1000 (Cell Signalling) and α-betaActin 1:3000 (Cell Signaling). We used 
goat α-mouse HRP 1:3000(Santa Cruz) and goat α-rabbit HRP 1:3000 (Santa 
Cruz) as secondary antibodies. To develop membrane, we used Amersham 
ECL Western Blotting Detection Reagent (GE Healthcare) and Amersham 
Hyperfilm ECL (GE Healthcare). 
 
Protein production in bacteria 
Codon Plus Competent Cells (Agilent Technology) were transformed with the 
plasmid of interest for bacterial expression. After screening, positive colonies 
were grown in LB broth + Ampicillin. Protein expression was induced with 
0.1mM Isopropyl ß-D-1-thiogalactopyranoside (ITPG, Sigma) for 3 hours at 
37oC. Bacteria were lysed with a Sonicator in GST-buffer (Tris-HCl 1M pH 7,5, 
NaCl 4M, EDTA 200 µM, dH2O). Recombinant protein was purified from the 
lysate using Sepharose-Glutathione 4B resin (GE Healthcare) After incubation 
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with the resin at 4oC overnight, recombinant protein was washed in GST-buffer 
and its molecular weight was detected by electrophoresis using SDS-page 
gels (Biorad) and Coomassie Brilliant Blue (Sigma-Aldrich) staining. 
 
Co-IP experiments 
SKBR3 and MDA-MB-231 cell lines were previously transfected with the 
constructs of interest. After 48 hours, cells were lysed as described before, the 
total proteins amount was normalized by Bradford assay and the same amount 
of total protein was incubated with the anti-FLAG M2 affinity gel resin (Sigma-
Aldrich) previously equilibrated with EB-buffer. The binding assay was 
performed overnight at 4oC in agitation. To remove the unbound proteins, resin 
after incubation was washed five times with EB-buffer and centrifuged. Tagged 
proteins were detached using 10% SDS and proteins were loaded on SDS-
page and detected using western blot by specific antibodies. 
 
Pull-down experiments 
For the pull-down assay, GST-SH3BGRL3 fusion protein was synthetized and 
bound to a Sepharose-Glutathione resin as previously described [57]. SKBR3 
cell line was lysed and normalized to the total protein amount. The same 
amount of total proteins was incubated with GST-fusion protein overnight at 
4oC in agitation. The binding was performed using EB-buffer added with CaCl2 
1mM or with EGTA 5mM. Unbounded proteins were washed 5 times in EB-
buffer (with CaCl2 1mM or with EGTA 5mM, respectively) and centrifuged. 
Tagged proteins were detached using 10% SDS and proteins were loaded on 
SDS-page and detected, using western blot, by specific antibodies. 
 
Migration and Invasiveness assays 
We tested migration and invasion capability after SH3BGRL3 and SH3BGRL 
gene silencing in MDA-MB-231 cell line. We down-regulated SH3BGRL3 
expression by using two different Silenced Select Pre-designed siRNA 
(Ambion). We also used a scrambled siRNA (Ambion) as a negative control. 
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Cells were plated in 6-wells plates (Corning) in DMEM + 10% FBS + 1% 
Pen/Strep + 1% Glutamax and after 24 hours from the plating, siRNAs were 
introduced in the cells by transfection using Lipofectamine 2000 (Thermo 
Fisher Scientific) according to the manufacture’s protocol. 48 hours after cell 
transfection, cells were starved using DMEM + 1% Pen/Strep + 1% Glutamax 
without FBS. After 8-10 hours of starvation, 25’000 cells were seeded in 
Boyden Chambers (Migration Support for 24 Well Plate with Transparent PET 
Membrane 8.0 µM pore size, Corning) or in Transwell covered by Matrigel 
(BioCoatTM Matrigel® Invasion Chambers PET Membrane 8.0 µM pore size, 
Corning). After 16 hours of migration, cells were removed from the top using 
Cristal Violet 1% (Sigma-Aldrich) and Glutaraldehyde 5% (Sigma-Aldrich), 
respectively [62]. Cells were counted in double-blind. 
 
Immunofluorescence 
After cell transfection with pCMV-FLAG/SH3BGR3 and pCMV-FLAG 
contructs, MDA-MB-231 cells were seeded on glasses for microscopy and 
fixed with Paraformaldehyde 3% (Sigma-Aldrich) before staining. For 
intracellular fluorescence, cell permeabilization was performed using Triton X-
100 0,1% (Sigma-Aldrich). PBS (Invitrogen, Thermo Fisher) + BSA 0,5% 
(Sigma-Aldrich) was used as a washing buffer while PBS+ BSA 2% was used 
for the saturation. We used α-FLAG (Sigma-Aldrich), α-Myo1c (Sigma-Aldrich) 
and Phalloidin Alexa Fluor-488 (Sigma-Aldrich) as primary antibodies while 
Alexa Fluor 488 goat α-rabbit (Life Technology) and Alexa Fluor 546 goat α-
rabbit (Life Technology) were used as secondary antibodies. DAPI (Abcam) 
was used for the nuclear stain. 
 
Scratch assay 
MCF-7 cells were grown in complete medium and seeded into 24-well tissue 
culture plate (Corning). At ca. 70-80% confluence as a monolayer, cells were 
starved for 12 hours in medium serum free. Gently and slowly, we performed 
the scratch using a 200µL pipette tip across the middle of the well. Wells were 
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washed with PBS to remove the detached cells and replenished with fresh 
complete medium. Pictures have been taken at time 0, 24 and 48 hours after 
the scratch. The gap distance was evaluated using ImageJ software and the 
% of the closure was calculate by the formula: % of wound closure = [(Areat=0h- 
Areat=∆h)/ Areat=0h] x100 [63]. 
 
Proliferation assay 
Cell growth has been evaluated by the xCELLigence system (Agilent) real-time 
cell analysis (RTCA) via the measurement of cell-induced electrical impedance 
[64], following the manufacturer’s protocol. 5’000 cells were seeded in E-Plate 
VIEW 16 (Agilent) covered by collagen (Sigma-Aldrich) and cell growth (Slope) 
was followed until 96 hours. In order to investigate the effect of the Tamoxifen, 
MCF-7 over-expressing SH3BGRL3 and control MCF-7 have been treated 
with 1µM of 4’OH-Tamoxifen (Sigma-Aldrich) dissolved in DMSO [65], 24 
hours after plating. Medium has been changed every 48 hours and cell growth 
was followed until 200 hours from the plating. 
 
Exosomes isolation from MDA-MB-231 cell line 
At ca. 70% of confluence, complete culture medium was removed and cells 
were washed 3 times with sterile PBS (Thermo Fischer Scientific). DMEM 
(Thermo Fischer Scientific) was added without FCS and cells have been 
incubated for 72 hours and successively the supernatant was collected and 
centrifuged at 300g for 10 minutes at 4oC to remove cells and debris. 
Subsequently, the supernatant was at 2’000g for 20 minutes, at 1’000g for 30 
minutes at 4°C and finally 100’000g for 90 minutes at 4oC, in order to pellet the 
exosomes. The supernatant was gently removed and the pellet resuspended 
in PBS. A final centrifugation was performed at 100’000g for 70 minutes at 
4oC. Once the supernatant was removed, the pellet containing the 




Mitochondria isolation from MDA-MB-231 cell line 
MDA-MB-231 were grown in complete medium and mitochondria were isolated 
from 2x107 cells. We performed a high-purity isolation using QproteomeTM 
Mitochondria Isolation Kit (QIAGEN) following the manufacturer’s protocol. 
After purification, the mitochondria pellet was lysed using RIPA buffer (Sigma-
Aldrich). 
 
Mammosphere formation assay 
A single cell suspension of control MCF-7 cells or SH3BGRL3 over-expressing 
MCF-7 cells was prepared using enzymatic (1x Trypsin-EDTA, Sigma-Aldrich), 
and manual disaggregation (25gauge needle) [66]. Cells were then plated at 
a density of 500 cells/cm2 in mammosphere medium (DMEM-F12/ B27 / 20-
ng/ml EGF/PenStrep) in non-adherent conditions in culture dishes coated with 
2-hydroxyethylmethacrylate (poly-HEMA, Sigma-Aldirch). Cells were grown 
for 5 days and maintained in a humidified incubator at 37°C at an atmospheric 
pressure in 5% carbon dioxide/air (v/v). After 5 days for culture, spheres > 50 
μM were counted using an eye piece graticule, and the percentage of cells 
plated which formed spheres was calculated and is referred to as percentage 
at mammosphere formation. Mammosphere assays were performed in 
triplicate and repeated three times independently. 
 
Metabolic flux analysis  
Extracellular acidification rates (ECAR) and real-time oxygen consumption 
rates (OCR) for MCF7 cells were determined using the Seahorse Extracellular 
Flux (XFe96) analyzer (Seahorse Bioscience). Briefly, 15’000 control MCF-7 
cells and SH3BGRL3 over-expressing MCF-7 cells per well were seeded into 
XFe-96 well cell culture plates for 24h. Then, cells were washed in pre-warmed 
XF assay media (or for OCR measurement, XF assay media supplemented 
with 10mM glucose, 1mM Pyruvate, 2mM L-glutamine and adjusted at 7.4 pH). 
Cells were then maintained in 175 µL/well of XF assay media at 37oC, in a 
non-CO2 incubator for 1 hour. During the incubation time, 5µL of 80mM 
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glucose, 9µM oligomycin, and 1M 2-deoxyglucose (for ECAR measurement) 
or 10µM oligomycin, 9 µM FCCP, 10 µM Rotenone, 10 µM antimycin A (for 
OCR measurement), were loaded in XF assay y media into the injection ports 
in the XFe96 sensor cartridge. Measurements were normalized by protein 
content (SRB assay). Data sets were analyzed using XFe96 software and 
GraphPad Prism software, using one-way ANOVA and Student’s t-test 
calculations [67]. 
 
Sulphorhodamine B (SRB) assay  
For the normalization of the Metabolic flux analysis, the cell viability was 
measured by Sulphorhodamine B assay (SRB, Sigma-Aldrich). The assay is 
based on the measurement of cellular protein contents. Cells were fixed with 
10% Trichloroacetic acid (TCA) for 1 hour at 4oC, and were dried overnight at 
room temperature. Then, plates were incubated with SRB for 30 minutes, 
washed twice with 1% acetic acid and air dried for at least 1hour. Finally, the 
protein-bound dye was dissolved in a 10mM Tris, pH 8.8, solution and read 
using a plate reader at 540-nm.  
 
Statistics 
For statistical comparison between samples, the Mann-Whitney U test was 
used for unpaired sample data and the Wilcoxon signed-rank test for paired 
sample data. Analyses were performed using the GraphPad Prism statistical 
software (GraphPad Software Inc., La Jolla, CA). Data are represented as the 
mean ± standard error of the mean (SEM), taken over ≥ 3 independent 
experiments, with ≥ 3 technical replicates per experiment, unless otherwise 








SH3BGRL3 binds Myo1c in a Ca2+-dependent manner 
Since calmodulin (CaM) binds Myo1c IQ domains in a calcium-dependent 
manner [33] and we previously demonstrated that also the SH3BRL3 protein 
is able to interact with Myo1c IQ domains [59], we investigated if also the 
binding of SH3BGRL3 to Myo1c was calcium dependent. For that purpose, we 
performed Co-IP and pull-down assays on SKBR3 cell lysates with or without 
calcium to demonstrated if the binding between SH3BGRL3 and Myo1c 
requires Ca2+ for its formation. For Co-IP experiments, SKBR3 cell line was 
transiently transfected with FLAG-SH3BGRL3 constructs with the FLAG vector 
alone as a control. Lysates were incubated at different Ca2+ concentration, 
pulled down using an anti-FLAG resin and analysed by SDS-PAGE and 
western blotting. Figure 8 shows that Ca2+ is able to influence the interaction 
between SH3BGRL3 and Myo1c since the intensity of the band related to the 
Ca2+ condition is clearly more intense than the one in the presence of EGTA.  
 
Figure 8 Co-IP using FLAG-SH3BGRL3 as a bait in SKBR3 cell line. Cells were transfected 
with pCMV/FLAG (Mock) and FLAG-SH3BGRL3. After Co-IP with anti-FLAG resin, in different 
Ca2+ concentration, samples were run on SDS-PAGE. We detected proteins using α-Myo1c 
and α-SH3BGRL3 antibodies. Lysates proteins are shown on the right and Co-IP proteins on 
the left. This experiment shows that there is a larger quantity of assembled SH3BGRL3/Myo1c 
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complexes in the presence of Ca2+. It also shows that EGTA (a compound that sequesters 




However, since Co-IP assay is a technique that reveals mainly complexes 
already assembled inside the cell, it isn’t the best choice to evaluate the 
formation of a new ones. For this reason, we performed a pull-down assay on 
SKBR3 lysates using recombinant GST-SH3BGRL3 and modulating the 
binding conditions (with EGTA or Ca2+). According to this, we can simply justify 
the presence of a signal in the Co-IP with EGTA (Figure 8 on the left)	since 
this compound is not able to interfere with complexes already assembled 
inside the cell. 
We first expressed a GST-SH3BGRL3 fusion protein using a construct (pGEX-
6p-1/SH3BGRL3) suitable for bacterial expression carrying SH3BGRL3 
preceded by a GST tag at the N-terminal of our protein and then we purified 
GST-SH3BGRL3 fusion protein using a Sepharose-Glutathione resin. We 
used the Glutathione-GST-SH3BGRL3 complex to pull-down Myo1c in wild 
type SKBR3 lysates at different Ca2+ concentrations. A Glutathione-GST alone 
has been used as a negative control. The result of the pull-down shows clearly 
that GST-SH3BGRL3 binds endogenous Myo1c in SKBR3 lysates in presence 
of Ca2+, while the binding doesn’t in the presence of EGTA. (Figure 9). The 
result of this experiment also indicates that the presence of EGTA in the Co-
IP procedure (Figure 9, on the left) is not able to interfere with the complexes 




Figure 9. Pull-down of Myo1c in SKBR3 cell line by using GST-SH3BGRL3. Cells lysate were 
incubated with Glutathione-GST-SH3BGRL3 at different Ca2+ concentration (with Ca2+ or using 
EGTA to sequester Ca2+). The samples were run on SDS-PAGE and proteins were detected 
in WB by using α-Myo1c antibody. Samples incubated with Glutathione-GST as negative 
control are shown on the left, followed by the pull-down results and lysates on the right. 
 
 
These results clearly show that SH3BGRL3 binds Myo1c in a Ca2+-dependent 
manner. Interestingly, also calmodulin binds Myo1c via neck region in a Ca2+-
dependent manner, but the CaM/Myo1c interaction occurs mostly in absence 
of Ca2+ [35, 37] whereas SH3BGRL3 binds Myo1c in presence of Ca2+, 
suggesting a possible complementary role of calmodulin and SHBGRL3 in 
Myo1c “neck” region regulation. 
Since Co-IP and pull-down experiments were made in the whole cell lysate 
containing lots of other proteins, we were interested to determine if the binding 
between SH3BGRL3 and Myo1c was direct or if there were other proteins 
mediating this interaction and to do this we planned to investigate the minimum 
binding conditions using only SH3BGRL3 and Myo1c as recombinant proteins 
in in vitro reactions. At first, we cloned SH3BGRL3 gene into a pQE-30 vector 
tagged with a tail of six Histidine (His) at the N-terminal and we expressed his-
SH3BGRL3 recombinant protein using the bacteria system followed by its 
purification using Nickel-NTA Agarose beads. Subsequently we cloned Myo1c  
gene into a pGEX-6-P-1 vector for the expression of a fusion protein tagged 
with a GST-tag at the N-terminal. The full GST-Myo1c recombinant protein 
production turned out to be very hard since just the only Myo1c is around 120 
KDa and enriched of post-translation modification reveling it too complex for 
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the bacteria expression system. So we decide to synthesize a construct 
carrying only Myo1c “neck” region (IQ domains with a GST tag) that we 
previously demonstrated to be the Myo1c region involved in the interaction 
with SH3BGRL3 (data not shown). Also in this case, it was impossible to 
produce any “neck” region of Myo1c in the bacteria system and after lots of 
failed attempts to find out the best way to product the recombinant protein, the 
question if the interaction between SH3BGRL3 and Myo1c is direct or 
mediated by other protein is still opened. 
 
 
SH3BGRL3 does not bind to pre-assembled SH3BGRL/Myo1c 
complexes 
Since we previously found that SH3BGRL3 and SH3BGRL proteins were both 
able to interact with Myo1c in SKBR3 cell line (and in particularly that 
SH3BGRL3 binds Myo1c IQ domains) [59, 61, 62], we investigated if 
SH3BGRL3 and SH3BGRL proteins could be both present in the complex with 
the Myo1c. To do this we transfected SKBR3 cell line with the vectors 
pCMV/FLAG-SH3BGRL and pBiGFP/SH3BGRL3, with pCMV/FLAG-
SH3BGRL alone as positive control and with pCMV/FLAG alone as negative 
control. Subsequently, transfected cells have been lysate and these lysates 
were incubated with an anti-FLAG resin to evaluate the binding with the 
Myo1c. We run samples on SDS-PAGE and detected proteins using specific 
antibodies α-Myo1c, α-SH3BGRL and α-SH3BGRL3. Western blot results 
(Figure 10) show that SH3BGRL is able to co-immunoprecipitate (Co-iP) 
Myo1c but not SH3BGRL3. This result reveals that the interaction between 
Myo1c and SH3BGRL is exclusive, not allowing its interaction with SH3BGRL3 
which is also able to interact with Myo1c when it is not already involved in the 
interaction with SH3BGRL and this may suggest a different role of the 





Figure 10. Co-IP using FLAG-SH3BGRL as a bait in SKBR3 cell line. Cells were transfected 
with pCMV/FLAG (Mock), FLAG-SH3BGRL plus SH3BGRL and FLAG-SH3BGRL only. After 
Co-IP with anti-FLAG resin and samples run on SDS-PAGE we detected proteins using α-
Myo1c, α-SH3BGRL and α-SH3BGRL3 antibodies. Lysates proteins are shown on the right 
and Co-IP proteins on the left. As we already demonstrated, SH3BGRL is able to Co-IP Myo1c 
and we revealed that in this complex (SH3BGRL/Myo1c) is not present SH3BGRL3 that is 







Evaluation of SH3BGRL3, SH3BGRL and Myo1c protein 
expression in different breast cancer cell line 
Founding that SH3BGRL3 and SH3BGRL proteins interact with Myo1c, in 
SKBR3 cell line, lead us to investigate a possible role of the complex that they 
form. Since Myo1c is a protein involved in cell membrane and cytoskeleton 
dynamics, we choose to evaluate SH3BGRL3 and SH3BGRL involvement in 
cell motility. At first, we choose to silence the SH3BGRL3 and the SH3BGRL 
expression in order to evaluate their involvement in cell migration and invasion  
For this purpose, we analysed a proper cellular model that was able to migrate. 
We checked different breast cancer cell lines (MDA-MB-231, SKBR3, MCF-7, 
MDA-MB-468, T47D and BT-474) and we found in the highly invasive MDA-
MB-231 cell line, a breast cancer cell line derived from a metastatic site [68] 
which is a typical cell line used for invasiveness experiments, the only one with 
a high expression of both SH3BGRL3, SH3BGRL and Myo1c (Figure 11). 
 
 
Figure 11. Western blot showing the different expression of SH3BGRL, SH3BGRL3 and 
Myo1c proteins in MDA-MB-231, SKBR3, MCF-7, MDA-MB-468, T47D and BT-474 breast 
cancer cell lines. Lysates were collected, run on SDS-PAGE and proteins were detected using 
α-SH3BGRL, α-SH3BGRL3, α-Myo1c and α-GAPDH (as a control). The highly invasive MDA-
MB-231 cell line shows a high expression of both our proteins suggesting it as a good model 
where to test if a down-expression of SH3BGRL and SH3BGRL3 may impair cell migration 
and invasiveness in this model. 
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SH3BGRL3 binds Myo1c in MDA-MB-231 cell line 
After having proved the expression of SH3BGRL3 protein in the MDA-MB-231 
cell line, we wanted to verify its ability to form intracellular complexes with the 
Myo1c protein also this cell model. To do this we performed Co-IP experiments 
as well as co-localization experiments in the MDA-MB-231 model. For the Co-
IP, we transiently transfected MDA-MB.231 cells with a specific construct for 
the expression of the FLAG-SH3BGRL3 fusion protein while a vector for the 
FLAG expression alone was used as a control, then we incubated the lysates 
with a FLAG binding resin. We found that also in the highly invasive MDA-MB-
231 cell line SH3BGRL3 is able to interact with the Myo1c molecular motor 
(Figure 12), differently from the negative control.  
 
 
Figure 12. Co-IP of endogenous Myo1c in the MDA-MB-231 cell line after transfection with 
FLAG-SH3BGRL3 and FLAG alone as a control. After incubation with an anti-FLAG resin, 
samples were run on SDS-PAGE and proteins were detected by western blot using α-
SH3BGRL3, α-Myo1c and α-FLAG antibodies (Co-IP results are shown on the top while 
lysates are on the bottom). 
 
 
To validate this data and to identify the localization of SH3BGRL3/Myo1c 
complexes we performed co-localization experiments by fluorescence assay. 
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In order to do this, we previously transfected MDA-MB-231 cells by a FLAG-
SH3BGRL3 since there was not an α-SH3BGRL3 antibody available for 
fluorescence staining. We used an antibody α-FLAG (to detect SH3BGRL3 
protein) and an α-Myo1c antibody both suitable for fluorescence staining, 
founding a similar expression pattern of these two proteins as it is shown in 
figure 13.A. Since cellular motility requires the involvement of F-actin [69] we 
investigated also actin pattern together with SH3BGRL3 and Myo1c, using 
Phalloidin to stain the actin, determining the distribution of SH3BGRL3, Myo1c 
and actin in the MDA-MB-231 cell line (Figure 13.B-C). 
 
 
Figure 13.A. Immunofluorescence staining using anti- FLAG antibody (to detect SH3BGRL3 
after transfection with FLAG- SH3BGRL3) and anti-Myo1C and Phalloidin (to detect F-actin) 
on co-localization of Myo1c and SH3BGRL3; B. anti-Myo1c and Phalloidin; C. SH3BGRL3 
and Phalloidin. We report that SH3BGRL3 and Myo1c have a similar distribution pattern and 
co-localize with actin-enriched structures beneeth the cell membrane. 
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Our data show that SH3BGRL3 and My1c are proteins that interact together 
and localize in the same cell membrane areas of actin-enriched structures this 
may suggest the involvement of these proteins in cell membrane dynamics 
and/or cell motility. 
 
 
SH3BGRL3 down-regulation impairs invasion and migration 
capacity of MDA-MB-231 cell line 
After we demonstrated SH3BGRL3 and Myo1c proteins are able to interact, 
we evaluated the SH3BGRL3 role in cell migration and invasion down-
regulating SH3BGRL3 expression in the MDA-MB-231 cell line by using 
specific siRNAs against the SH3BGRL3 gene and using scrambled unspecific 
siRNA as a negative control. At first, we silenced SH3BGRL3 by two different 
siRNAs (here called SIRNA1 and SIRNA2) as it is shown in Figure 14.B and in 
Figure 14.C. We used Boyden chambers for the migration assay which detect 
the ability of MDA-MB-231 to migrate throw a membrane with specific pores 
size, while for the invasion assay the same chambers, but covered with 
Matrigel, have been used to analyse the ability of the cells to digest 
extracellular matrix, an essential step in the metastatic process (see Materials 
and Methods). The result of the migration assays, performed with two different 
siRNAs, shows a statistically significant decrease in the migration capacity of 
silenced MDA-MB-231 cells respect to the control as is showed in Figure 14.A. 
This data that suggests SH3BGRL3 is as a protein that plays a crucial role in 
cell migration, according to what Chiang and colleagues have reported [16]. 
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Figure 14. A. This figure shows that the SH3BGRL3 down-regulation decreases, in a 
statistically significant fashion, the MDA-MB-231 migratory capability, evaluated using Boyden 
chamber. Pictures were taken on a light microscope from the bottom side of the Transwell 
membrane and cells were counted after fixation and staining using crystal violet. B. and C. 
show the western blot and their relative quantification of SH3BGRL3 silencing by using two 
different and specific siRNAs. An unspecific scrambled siRNA was used as negative control. 
Lysate were collected and samples were run on SDS-PAGE and proteins were detected using 
































In order to evaluate the invasiveness, we performed invasion assay in MDA-
MB-231 cell line using Transwells covered with Matrigel to mimic the 
extracellular matrix, after SH3BGRL3 silencing by a specific siRNA and an 
unspecific scrambled siRNAs as a negative control to maintain their motility 
capacity. Here we show that the SH3BGRL3 down-regulation impairs 





Figure 15. A. shows that the SH3BGRL3 down-regulation decreases, in a statistically manner, 
the MDA-MB-231 invasiveness capability using Transwell chambers covered with Matrigel to 
analyse the ability of the cells to digest extracellular matrix. B. This panel shows the western 
blot and their relative quantification of SH3BGRL3 after silencing by using a specific siRNA 
while an unspecific scrambled siRNA was used as negative control. Lysate were collected, 
samples run on SDS-PAGE and proteins were detected using α-SH3BGRL3 and α-GAPDH 
as positive control. C. Pictures were taken with a light microscope (magnification 10X) from 
the bottom side of the Transwell membrane and cells were counted after fixation and staining 

















The SH3BGRL3 gene over-expression increases cell motility 
in MFC-7 cell line 
To validate the effect of SH3BGRL3 silencing in cell migration and invasion 
obtained with the MDA-MB-231 cell line model, we decided to test the cell 
motility in a different cell line and with a different kind of assay. To do this, we 
created a stable MCF-7 cell line over-expressing the SH3BGRL3 protein by a 
specific lentivirus carrying the sequence for SH3BGRL3 gene and a resistance 
for puromycin antibiotic (for the selection) while a lentivirus with the only 
antibiotic resistance was used as a negative control. After the cells had been 
selected, we verified SH3BGRL3 over-expression by western-blot technique 
using specific antibodies (Figure 16.B). We tested cell migration performing 
the wound healing assay (Scratch assay) to evaluate specifically the cell 
motility of SH3BGRL3 over-expressing MCF-7 cells versus control cells and 
we calculated the wound closure analysing. Pictures were taken at time 0, then 
24 hours and 48 hours after the scratch (Figure 16.C). According to what we 
found in MDA-MB-231 cells after the SH3BGRL3 gene silencing, also in the 
MCF-7   cells an over-expression of SH3BGRL3 increases cell motility of the 









Figure 16 A. SH3BGRL3 over-expression increases cell motility in the SH3BGRL3 over-
expressing MCF-7 cell line compared to the control at 24 hours and 48 hours after the scratch. 
The scratch assay has been performed in a manual way using a 200 µL pippette tip after 12 
hours of cell starvation in DMEM without FBS. After the scratch the cells were put in complete 
medium for 48 hours. The wound closure area was evaluated by imageJ program and the % 
of the closure was calculate by the formula: % of wound closure = [(Areat=0h- Areat=∆h)/ 
Areat=0h]x100. B. We evaluated the SH3BGRL3 expression in MDA-MB-231 cells (as a 
positive control), in MFC-7 control cells (Lv-105) and MCF-7 cells over-expressing the 
SH3BGRL3 gene. C. Pictures of the wound closure were taken with a light microscope 
(magnification 10X) at time 0, 24 hours and 48 hours after the scratch. 
 
 
The SH3BGRL3 gene over-expression does not affect cell 
growth/proliferation in MFC-7 cell line 
To be sure that the differences observed in the wound closure between the 
SH3BGRL3 over-expressing MCF-7 cells and control cells were due only by a 
different cell motility and not by a different on the cell growth, we performed a 
cell growth assay using the xCELLigence real-time cell analysis (RTCA) 
system. The SH3BGRL3 over-expression MCF-7 cells and MCF-7 control cells 
were plated at the same concentration and cell growth was followed for 96 
hours after plating. As it is shown in Figure 17.A, no difference between in cell 
growth of SH3BGRL3 over-expressing MCF-7 cells and MCF-7 control cells 
were observed. In some instance, we evaluated also the cell growth within 48 
hours (time range of the scratch assay) without finding any difference between 





Figure 17. A. Cell growth assay performed by the xCELLigence system real-time cell analysis 
(RTCA). Cell growth (as a slope inclination of the Cell Index curve in a particular user-defined 
time range) was evaluated from time 0 to 48 hours after cell plating demonstrating that there 
is no difference in this time range between MCF-7 control (blue) and MCF-7 SH3BGRL3 over-
expressing (pink) assuming that the only difference in the wound closure that we found 
depends only in differences in cell motility. B. Slope cell growth evaluation from 0 hours to 96 
hours, no difference was founded neither here. C. Normalized cell index curve that show 
clearly how there is no difference in cell growth between MCF-7 SH3BGRL3 over-expressing 






SH3BGRL down-regulation does not affect migration and 
invasion capacity of MDA-MB-231 cell line 
SH3BGRL belongs to the same family of SH3BGRL3 and shows a high 
homology with it. We demonstrated that also SH3BGRL is able to Co-IP Myo1c 
in SK-BR-3 cell line [58]. According to this, we performed migration and 
invasion assays in the highly invasive MDA-MB-231cell line after silencing or 
not of the SH3BGRL gene. As we performed before for SH3BGRL3, we used 
Boyden chamber to evaluate the migration capability while Transwells covered 
with Matrigel were used for the invasion assay. We silenced SH3BGRL 
expression by using a specific siRNA directed to its genomic sequence while 
an unspecific scrambled siRNA was used as a negative control. Differently 
from what we found in the SH3BGRL3 silencing experiments, a down-
expression of SH3BGRL doesn’t impair cell migration (Figure 18) and cell 




Figure 18 A. Results of the migration assays, after SH3BGRL silencing in the MDA-MB-231 
cell model, using Boyden chamber. The difference in cells number is not statistically significant 
Pictures were taken with a light microscope from the bottom side of the Transwell membrane 
and cells were counted after fixation and staining using crystal violet. B. This panel shows the 
western blot and its relative quantification of SH3BGRL silencing by using a specific siRNA 
while un unspecific scrambled siRNA was used as negative control. Lysate were collected and 
samples were run on SDS-PAGE and proteins were detected using α-SH3BGRL and α-




















Figure 19 A. Here we show as a SH3BGRL doesn’t decreases MDA-MB-231 invasiveness 
capability either using Transwell chamber covered by Matrigel to analyse the ability of the cell 
to digest extracellular matrix. B. It is shown the western blot and its relative quantification of 
SH3BGRL silencing by using a specific siRNAs while an unspecific scrambled siRNA was 
used as negative control. Lysate were collected and samples were run on SDS-PAGE and 
proteins were detected using α-SH3BGRL and α-GAPDH as positive control. C. Pictures were 
taken on a light microscopy (magnification 10X) from the bottom side of the Transwell 


















SH3BGRL does not Co-IP Myo1c in MDA-MB-231 cell line 
Since we didn’t find any correlation between SH3BBGRL expression and 
migration or invasion capability of MDA-MB-231 cell line, we investigated if 
SH3BGRL were able to form the complex with Myo1c, as SH3BGRL3 does. 
As we performed before for SH3BGRL3 analysis, we transiently transfected 
MDA-MB-231 cells with a specific construct for the expression of FLAG-
SH3BGRL while a vector for the only FLAG expression was used as a negative 
control. Subsequently we incubated the lysates with a specific resin binding 
the FLAG epitope. Despite to what we found for SH3BGRL3, no interaction 
between SH3BGRL and the Myo1c molecular motor was detected (Figure 20). 
These results can easily explain also the negative results obtained in the 




Figure 20. Co-IP of endogenous Myo1c in MDA-MB-231 cells after transfection with FLAG-
SH3BGRL and FLAG alone as a control. No Myo1c was Co-IP by SH3BGRL. After incubation 
with an anti-FLAG resin, samples were run on SDS-PAGE and proteins were detected by 
western blotting using α-SH3BGRL, α-Myo1c and α-FLAG antibodies (Co-IP results are 
shown on the top while lysates are on the bottom). 
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No interaction between SH3BGRL3 or SH3BGRL with ERBb2, 
EGFR and Grb2 were founded 
As already said, a published paper showed that SH3BGRL (or SH3BGRL3) 
was able to binds ErbB1 (EGFR) at the phosphorylated tyrosine Y891 and 
ErbB2 at phosphorylated Y923 and Y1196 by proteomyc analysis [54]. We 
performed Co-IP experiments to validate this.  At first, we transiently 
transfected SKBR3 cell line with FLAG-SH3BGRL3 and FLAG only as 
negative control and we tried to Co-IP ErbB2 by using an anti-FLAG resin. 
Since this result was negative we tried te reversed Co-IP (using ErbB2 as bait) 
that was negative too (data not shown), thus we assumed that there was no 
interaction between SH3BGRL3 and ErbB2 receptor. Recently, accordingly to 
data reported by Chiang and collegueas that found SH3BGR3 positively 
associated with higher histologic grading and muscle invasiveness of urothelial 
carcinoma and able to interact with phosphor-EGFR at Y1068, Y1086, and 
Y1173 through Grb2 by its proline-rich motif and activates the Akt-associated 
signalling pathway [23] we were interested to investigate the interaction 
between SH3BGRL3 and Grb2 also in MDA-MB-231 cell line we already 
correlated SH3BGRL3 function with the cell migration and invasion. Since we 
didn’t find that SH3BGRL3 could to Co-immunoprecipitate phosphor-EGFR 
after transiently transfection of MDA-MB-231 cells with FLAG-SH3BGRL3 and 
after EGFR treatment (data not shown), we tried then to demonstrate the 
interaction between SH3BGRL3 and ErbB2 in SKBR3 cells through Grb2 
adaptor protein. For this purpose, we transiently transfected SKBR3 cell line 
with FLAG-SH3BGRL3 and FLAG alone as negative control. We incubated 
cell lysates with an anti-FLAG resin and we detected proteins by WB. Figure 
21 shows that no interaction between SH3BGRL3 (or SH3BGRL) and Grb2 
proteins was found. Of note, SH3BGRL3 protein e doesn’t present a usual 
SH3-binding domain that can interact with Grb2. 
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Figure 21. Grb2 Co-IP using SH3BGRL3 or SH3BGRL as a bait, no interaction was founded 
in SKBR3 cell line lysates. We used Myo1c Co-IP as positive control. Cells were transiently 
transfected with constructs coding for FLAG-SH3BGRL (and SH3BGRL3), FLAG-SH3BGRL3 
alone or FLAG alone as negative control. Lysates (on the left) were incubates with an anti-
FLAG resin, run on SDS-page and blotted proteins band were detected on WB using α-Myo1c, 
α-SH3BGRL3, α-SH3BGRL and α-Myo1c antibodies. Co-IP results are shown on the right. 
 
 
SH3BGRL3 is a cytosolic protein that is not found in the 
mitochondrial fraction 
To further lighten the SH3BGRL3 function and its involvement in cell motility 
we invastigated the presence of the SH3BGRL3 protein in isolated 
mitochondria purified from MDA-MB-231 cells. We decided to investigate the 
presence of SH3BGRL3 in mitochondria since is been reported recently in the 
litterature how mitochondrial dynamics regulates migration and invasion of 
breast cancer cell [70]. Mitochondria are organelles that provide the majority 
of the energy in most cells. Since mitochondria balance is maintained by two 
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opposing processes called fission and fusion, in cancer cells dysfunction of 
mitochondria has been implicated in processes involved in tumorigenesis such 
as metastasis [71]. Cancer cells exhibited an excess of mitochondrial fission 
and impaired mitochondrial fusion that are involved in breast cancer cell 
migration and invasion (e.g. MDA-MB-231). In breast cancer cells, also 
lamellipodia formation depends on the mitochondria dynamics. According to 
this we isolated mitochondria from MDA-MB-231 cells and after mitochondria 
lysis we analysed the expression of SH3BGRL3 by western blot. No 
SH3BGRL3 signal was founded in isolated mitochondria (Figure 22), 
suggesting that SH3BGRL3 is a cytosolic protein that does not belonging to 
the mitochondrial fraction. 
 
 
Figure 22. Analysis of SH3BGRL3 presence in isolated mitochondria by western blot. 
SH3BGRL3 was not found in mitochondria isolated from MDA-MB-231 breast cancer cell line. 




Myo1c as a novel exosomal marker of microvescicles isolated 
from the highly invasive MDA-MB-231 cell line 
According to what recent reported papers about the presence of SH3BGRL3 
in the secretome or urine of patients with different types of tumor (e.g. 
urothelial carcinoma, papillary thyroid carcinoma, lung adenocarcinoma), data 
that suggests SH3BGRL3 as an extracellular protein associated with a higher 
histologic grading and muscle invasiveness of these type of tumor [23], we 
investigated the presence of SH3BGRL3 in the microvesicle population 
secreted by the highly invasive MDA-MB-231 cell line. After media 
ultracentrifugation, microvesiscles were lysated and protein were detected by 
western blot technique using α-Alix (as an exosomal marker), α-Myo1c (as an 
intracellular marker), α-SH3BGRL and α-SH3BGRL3 antibodies. We didn’t 
find SH3BGRL3 protein as well as SH3BGRL protein in the microvesicle 
lysates but a clear band was found for the Myo1c (Figure 23) suggesting this 
protein as a possible novel exosomal marker. Since Myo1c is a protein able to 
interact with actin-cytoskeleton and the cell membrane, it sounds possible that 
it may be involved in microvescicles formation and in their movement to the 
plasma membrane for the secretion in the outside environment. 
 
 
Figure 23. A. Microvesicles isolation from MDA-MB-231 cells. Conditioned media was 
collected after 72h of incubation and centrifuged at different speeds to remove dead cells, cell 
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debris and macrovesicles. The micovesicles pellet was lysed and protein were detected by 
western blot analysis using α-Alix (as a specific exosomal marker), α-Myo1c (as an 
intracellular marker), α-SH3BGRL and α-SH3BGRL3 antibodies. No SH3BGRL3 and 
SH3BGRL signal were detected. We founded Myo1c enrichment in exosomal lysate 
suggesting it as a new potential marker of exosomes isolated from MDA-MB-231 cell line. 
Exosomal lysate is shown on the left and cellular lysate on the right. B. Western blotting 
membrane after red pounceau staining. Though exosome proteins are less than cellular 




SH3BGRL3 increases cell metabolism in the SH3BGRL3 over-
expressing MCF-7 cells 
A cell that migrates and spreads into different part of the organism requires 
lots of energy in order to satisfy all the changes in cytoskeleton/plasma 
membrane rearrangements (e.g. formation of lamellipodia, psedudopodia or 
fillipodia), the capability to digest the extra-cellular matrix (invasion) and the 
synthesis and secretion of new proteins [73]. For this reason, we evaluated the 
metabolism (glycolysis and mitochondria respiration) of the SH3BGRL3 over-
expressing MCF-7 cells compared to control MCF-7 cells by analysing the 
metabolic flux with the Seahorse XFe96. Interestingly, Figure 24 illustrates 
that the SH3BGRL3 over-expressing MCF-7 cells show a large increase in the 
oxygen consumption rates (OCR) compared to control MCF-7 cells, processed 
in parallel. Also glycolysis was increased, as measured by the ECAR 
(extracellular acidification rate) (Figure 25). By these results the SH3BGRL3 
over-expressing MCF-7 cells seem to be more glycolytic and shown an 
increase also in the OCR compared to the control MCF-7 cells. 
 49 
 
Figure 24. SH3BGRL3 increases mitochondrial respiration in the SH3BGRL3 over-expressing 
MCF-7 cells. The metabolic profile of MCF-7 monolayers was assessed using the Seahorse 
XFe96 analyzer. At the top is shown a representative tracing of metabolic flux, at the bottom 
is reported a significant increase in basal respiration, proton leak and maximal respiration of 




Figure 25. Glycolysis is increased in the SH3BGRL3 over-expressing MCF-7 cells. 
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The metabolic profile of MCF-7 monolayers was assessed using the Seahorse XF-e96 
analyzer. At the top is shown a representative tracing of metabolic flux, at the bottom the 
analysis of the samples shown an increase in glycolysis, glycolytic reserve and glycolytic 
reserve capacity as well of the SH3BGRL3 over-expressing MCF-7 cells (red) compared to 
MCF-7 control cells (green). 
 
 
The SH3BGRL3 protein is not related to cell “stemness” 
performing mammosphere assay 
As migration and invasion are required for metastasis we were interested to 
evaluate if SH3BGRL3 is also involved in the cancer stem cell maintenance as 
a new potential stemness marker. To do this, we compared the SH3BGRL3 
over-expressing MCF-7 cells to control MCF-7 cells performing mammosphere 
assay. Figure 26 shows that no significantly differences in mammospheres 
formation were founded between SH3BGRL3 over-expressing MFC-7 cells 
and MCF-7 control cells. This result suggests that the SH3BGRL3 protein is 
not involved in “stemness” property of the cell though both cell motility and 
“stemness” take part in the metastatic process [74].  
 
 
Figure 26. Mammosphere formation in the SH3BGRL3 over-expressing MCF-7 cells versus 
control MCF-7 cells. The result shows as no differences were founded between the samples. 





























control MCF7 cells cultured in low attachment plates for 5 days before counting. The data 
shown are the mean ± SEM of 3 independent experiments performed in triplicate. p < 0.05. 
 
 
SH3BGRL3 implicates Estrogen Receptor-alpha 
downregulation and the resistance to 4’OH-Tamoxifen in 
SH3BGRL3 over-expressing MCF-7 cells 
It has been recently reported in the literature a possible correlation between 
the SH3BGRL3 protein and the Estrogen Receptor-alpha (ERα) expression. 
Since ERα silencing in MCF-7 cells induces several markers expression of the 
Epithelial-Mesenchymal Transition (EMT), the expression of EGFR and HER2 
receptors that increases cell proliferation, migration and invasion [74] and un 
up-regulation of the SH3BGRL3 gene expression in MCF-7 breast cancer [75] 
we decided to evaluate ERα expression in our model. We found a statistically 
significant reduction of the ERα expression in the SH3BGRL3 over-expressing 
MCF-7 cells compared to control MCF-7 cells (figure 26.A). This data 
suggests that SH3BGRL3 expression may be under ERα control, since its 
expression in down-regulated in ERα-positive breast cancer cell lines [76], 
considering that ERα is a transcription factor composed of domains able to 
bind the DNA to activate/repress the transcription of different genes [77]. It’s 
also interesting how the treatment with a combination of Estradiol (E2) and 
4’OH-Tamoxifen (4’OH-Tam), an active metabolite of Tamoxifen, significantly 
promotes cells motility on MCF-7 cell line [78]. Accordingly, we evaluated 
4’OH-Tam effect on the SH3BGRL3 over-expressing MCF-7 cells performing 
cell growth assays using the xCELLigence RTCA system. Since 4’OH-Tam is 
a partial agonist of estrogen receptors used for the treatment of estrogen 
receptor-positive (ER+) breast cancer [79,80] and its action in possible only on 
cancer ER-positive cells and not on ER-negative (e.g. MDA-MB-231), choose 
to investigate if theSH3BGRL3 over-expressing MCF-7 cells, that we found to 
show a reduction of ERα expression, ,may be resistant to 4’OH-Tam. 
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24 hours after cells plating, we treated them with 4’OH-Tam [1µM] for 200 
hours and we observed that the SH3BGRL3 over-expressing MCF-7 cell, that 
exhibit an ERα down-regulation expression, are more resistant to 4’OH-Tam 
compared to control MCF-7 cells (Figure 27). 
 
 
Figure 26. A Western blot analysis of ERα expression in the SH3BGRL3 over-expressing 
MCF-7 cells compared to control MCF-7 (Lv-105) cells. MDA-MB-231 cell lysate (right) was 
used as a positive control for SH3BGRL3 expression and as a negative one for ERα 




Figure 27. Cell growth assay performed by xCELLigence system real-time cell analysis 
(RTCA). The cells were treated with 4’OH-Tam (4-hydroxytamoxifen) 24 hours (time point of 
normalization) after plating and cell growth (as a slope inclination of the Cell Index curve in a 
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particular user-defined time range) was evaluated between 150 hours and 200 hours to 
appreciate any difference since 4’OH-Tam is a cytostatic drug. Media and 4’OH-Tam were 
changed every 48 hours. Comparing the slope (% vs CTRL) of the SH3BGRL3 over-
expressing MCF-7 cells to control MCF-7 cells we found a statistically significant increasing of 
cell growth in the SH3BGRL3 over-expressing MCF-7 cells after 4’-OH treatment respect to 





The aim of this project was to characterize the proteins belonging to the 
SH3BGR family, in particular we focused our study on the SH3BGRL and 
SH3BGRL3 proteins.  
After we found SH3BGRL3 and SH3BGRL proteins able to interact with the 
molecular motor Myo1c, more specifically SH3BGRL3 protein binds the Myo1c 
IQ domains, in SKBR3 breast cancer cell line [58], we wanted to investigate if 
Ca2+ could play a role in the SH3BGRL3/Myo1c complex formation since CaM 
is able to bind IQ domains in a low Ca2+ concentration [81]. We found that 
SH3BGRL3 protein binds Myo1c only in the presence of Ca2+, while this 
binding doesn’t occur in the presence of a Ca2+ chelator (e.g. EGTA). This 
suggests that SH3BGRL3 and CaM are two proteins that both bind Myo1c IQ 
domains but at different Ca2+ concentration, suggesting Ca2+-driven changes 
in the “neck” region of the Myo1c and this may modulate the Myo1c function 
based on Ca2+ concentration inside the cells. 
 
Since we previously demonstrated that both SH3BGRL and SH3BGRL3 
proteins are able to Co-IP Myo1c in SKBR3 model [58], we investigated if 
SH3BGRL and SH3BGRL3 may be simultaneously present in the complex 
with the Myo1C. Accordingly, we co-transfected the SKBR3 cell line with both 
SH3BGRL and SH3BGRL3 using SH3BGRL as a bait: we found that Myo1c 
co-immunoprecipitates whereas SH3BGRL3 doesn’t, indicating that the 
binding of SH3BGRL and SH3BGRL3 with Myo1c is mutually exclusive and 
this could suggest a different role between SH3BGRL and SH3BGRL3 
proteins. 
 
Since we have never succeeded to demonstrate any interaction between 
SH3BGRL3 (or SH3BGRL) with ErbB1 (or EGFR) and ErbB2, differently from 
what is reported in different studies [26, 55], we investigated the interaction 
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between the Grb2 adaptor protein and SH3BGRL3. We choose Grb2 because 
we though it could be the link between SH3BGRL3 and EGF-Receptors, since 
SH3BGRL3 lacks of the SH3-binding domain necessary to interact with the 
phosphorylated tyrosine of ErbB1 or ErbB2 [55]. Also in this way, no interaction 
between the SH3BGRL3 (or SH3BGRL) protein and Grb2 has been founded.  
 
Subsequently, we focused our experiments to investigate any possible 
function correlated to the SH3BGRL3 (or SH3BGRL)/Myo1c protein complex.  
Myo1c has multiple and different functions inside the cells and our results 
suggest SH3BGRL3 as a possible candidate in Myo1c regulation through its 
interaction via IQ domains. Since Chang and colleagues [26] found 
SH3BGRL3 in the urine of patients with urothelial carcinoma, an up-regulation 
in primary bladder cancer cells and its involvement in cancer cell proliferation, 
epithelial-mesenchymal transition (EMT) and cell migration, we decided to 
investigate the SH3BGRL3 role in cell migration and invasion that are both 
essential steps in cancer metastasis [82]. For this reason, we performed 
migration and invasion assays after SH3BGRL3 (or SH3BGRL) down-
regulation. At first, it was necessary to find another cell model (different from 
the SKBR3 cell line) and we found in the highly invasive MDA-MB-231 cell line 
a good model since these cells expressed both SH3BGRL3 and Myo1c 
proteins and form the complex together (verified by Co-immunoprecipitation 
and Co-localization experiments). 
Our data shows a decrease in migration and invasion capability of the MDA-
MB-231 cells when SH3BGRL3 gene in down-regulated, confirming what 
Chang and colleagues have been reported in their paper [26]. 
According to our data attended in the SKBR3 cell line, we also evaluated the 
SH3BGRL role in cell migration and invasion. Differently from SH3BGRL3, the 
SH3BGRL gene down-regulation doesn’t compromise MDA-MB-231 migration 
and invasion capability. As expected, Co-immunoprecipitation experiments 
were not able to demonstrate the SH3BGRL/Myo1c complex formation in the 
MDA-MB-231 cell line. 
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We are not able to explain this particular Myo1c behavior on its capacity to 
bind or not SH3BGRL protein among two different cell lines but we found in 
literature a similar behavior of the Myo1c protein on the binding with SHIP2 
interactor participating in the control of cell migration in 1321 N1 glioblastoma 
cells but not in COS-7 cell line [83]. 
To confirm our data about the SH3BGRL3 protein involvement in cell 
migration, we created a MCF-7 cell line stably over-expressing for the 
SH3BGRL3 gene. Using the scratch assay, we found an increase in the 
motility capability of this cell line. Since we didn’t find any difference in the cell 
growth, performing cell growth assays, as Chang et al. reported [26], we 
suggest SH3BGRL3 as a protein involved in the cell motility and not in the cell 
proliferation.  
 
Since a few recent papers [23, 24, 25, 26] suggested that SH3BGRL3 could 
be also secreted, and since secreted proteins are necessary for the cells 
invasiveness (e.g. metalloproteinase that are able to digest the Extracellular 
Matrix) and microvesicles like exosomes contain different molecules (proteins, 
lipids and nuclei acids) able to modify phenotype of normal target cell into a 
cancer one [84, 85], we isolated exosomes from MDA-MB-231 to investigate 
any SH3BGRL3 involvement in the microvesicles system but we didn’t find any 
SH3BGRL3 expression in exosomes secreted by the MDA-MB-231 cell line. 
Otherwise, a high amount of Myo1c has been founded suggesting Myo1c as 
a new microvesicles marker for the characterization of isolated exosomes from 
MDA-MB-231 cell line. 
 
Since during the metastatic process cancer cells require to preserve their 
“stemness” properties [86], we investigate SH3BGRL3 role in cell “stemness” 
performing a mammospheres assay that showed no correlation between 
SH3BGRL3 over-expressing MCF-7 cells and the ability of the cells to growth 
and proliferate in non-adherens conditions. Interestingly, we found an increase 
on the metabolic profile of the SH3BGRL3 over-expressing MFC-7 cells 
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respect to control MCF-7 cells based on oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) suggesting that these cells require a 
large amount of energy. We can explain these data looking at our results about 
the migration, cells able to migrate requires high level of ATP production to 
satisfy the cytoskeleton changes and plasma membrane remodelling during 
this process [87]. 
 
Recently, different studies have been reported an interesting correlation 
between Estrogen-Receptor Alpha (ERα) and SH3BGRL3 expression. It 
seems that ERα works as suppressor of SH3BGRL3 gene expression and that 
perhaps may explain the higher SH3BGRL3 protein amount in MDA-MB-231 
cell line (Estrogen-ReceptorAlpha negative) respect to the lower SH3BGRL3 
expression in MCF-7 cell line (Estrogen-Receptor positive) [76, 77, 78, 79, 80]. 
This can also explain the different ability to migrate between MDA-MB-231 and 
MCF- 7 cell lines [68] considering that ERα expression controls cell migration, 
stemness and EMT process [88]. According to these data and the literature, 
we found in the SH3BGRL3 over-expressing MCF-7 cells an increase of 
migration ability through scratch assay, a significant reduction on the ERα 
expression and we also demonstrated these cells to be more resistant to the 
4’OH-Tam treatment respect to control MCF-7. 
 
In the final analysis, our work and the poor literature about the SH3BGR family 
suggests that these proteins can have an important role in aggressiveness and 




CONCLUSIONS AND OBSERVATIONS OF THE THESIS 
 
SH3-Domain Binding Glutamic acid Rich Like 3 (SH3BGRL3) protein has 
enrolled as a potential tumorigenic protein through specific interactions with 
others proteins. In our work, we found that Co-IP could not confirm the 
interaction between SH3BGRL3 (or SH3BGRL) and ErBb2/EGFR/Grb2. 
 
 In addition, our results confirm the interaction of Myo1c with SH3BGRL3 
in SKBR3 and MDA-MB-231 breast cancer cell linesci which does not occur 
with SH3BGRL protein in the MDA-MB-231 model. 
 
Our functional studies further included that: 
 SH3BGRL3/Myo1c complex formation is Ca2+-dependent; 
 SH3BGRL3 AND Myo1c localise to the actin-enriched membrane area 
supporting their involvement in cell membrane and cytoskeleton dynamics; 
 There is a detectable expression difference among SH3BGRL and 
SH3BGRL3 proteins in breast cancer cell lines. Moreover, the expression of 
SH3BGRL3 seems to be characteristic in the Triple Negative Breas Cancer 
(TNBC) cell lines; 
 Inhibited SH3BGRL3 expression impairs migration/invasion capability 
of TNBC cell line (e.g. MDA-MB-231); 
 Over-expressing SH3BGRL3 increases cell motility and tamoxifen 
resistance without influencing the baseline proliferation of ER+ cell line that are 
originally SH3BGRL3 negative (e.g. MCF-7). 
 In parallel, we found another interesting observation from SH3BGRL3 
exosome expression study that Myo1c could be e potential microvesicle 
marker. 
 
Based on these, the SH3BGRL3 protein could influence cell motility, cell 





















5.	 Jutta	 Beneken,	 Jian	 Cheng,	 TuBo	 Xiao,	Mutsuo	Nuriya,	 Joseph	 P.	 Yuan,	 Paul	 F.	












7.	N.A.	 Bearda,	 D.R.	 Laverb,	 A.F.	 Dulhunty.	 Calsequestrin	 and	 the	 calcium	 release	
































15.	 Muñiz	 Lino	 MA,	 Palacios-Rodríguez	 Y,	 Rodríguez-Cuevas	 S,	 Bautista-Piña	 V,	
Marchat	 LA,	 et	 al.	 Comparative	 proteomic	 profiling	 of	 triple-negative	 breast	







Binds	 to	 AU-Rich	Domains	 in	 the	 3'	 Untranslated	 Regions	 of	 Rapidly	 Degraded	



























analysis	 of	 fine-needle-aspiration	 cystic	 fluid	 proteome,	 cancer	 cell	 secretome,	
and	 public	 transcriptome	 datasets	 for	 papillary	 thyroid	 cancer	 biomarker	
discovery.	Oncotarget	(2018)	Jan	4;9(15):12079-12100.	
	
25.	 Sanchez	 C.,	Mazzucchelli	 G.,	 Lambert	 C.,	 Comblain	 F.,	 DePauw	E.,	 Henrotin	 Y.	
omparison	 of	 secretome	 from	 osteoblasts	 derived	 from	 sclerotic	 versus	 non-
sclerotic	subchondral	bone	in	OA:	A	pilot	study.	PloS	One	2018;	13(3):	e0194591.		
	













29.	 Krendel	 M,	 Mooseker	 MS.	 Myosins:	 tails	 (and	 heads)	 of	 functional	 diversity.	
Physiology	(Bethesda).	2005;20:239-251.	
	













insights	 into	 calcium-mediated	 conformational	 coupling.	 Nat	 Struct	 Mol	 Biol.	
2015;22:81-88.	
	






























43.	 Hirono	 M,	 Denis	 CS,	 Richardson	 GP,	 Gillespie	 PG.	 Hair	 cells	 require	











46.	 Yip	MF,	 Ramm	G,	 Larance	M,	Hoehn	 KL,	Wagner	MC,	 et	 al.	 CaMKII-mediated	
phosphorylation	 of	 the	myosin	motor	Myo1c	 is	 required	 for	 insulin-stimulated	
GLUT4	translocation	in	adipocytes.	Cell	Metab.	2008;8:384-398.	
	
47.	 Capmany	A.,	 Yoshimura	 A.,	 Kerdous	 R.,	 Caorsi	 V.,	 Aurianne	 Lescure,	 Del	Nery	
E.,	Coudrier	E.,	Goud	B,	Schauer	K.	MYO1C	stabilizes	actin	and	facilitates	the	arrival	














Santos-Argumedo	 L.	 Myosin	 1c	 Participates	 in	 B	 Cell	 Cytoskeleton	
Rearrangements,	 Is	 Recruited	 to	 the	 Immunologic	 Synapse,	 and	Contributes	 to	
Antigen	Presentation.	J	Immunol.	187	(6)	3053-3063.	
	
52.	Wang	 FS,	 Liu	 CW,	 Diefenbach	 TJ,	 Jay	 DG.	Modeling	 the	 role	 of	 myosin	 1c	 in	
neuronal	growth	cone	turning.	Biophys	J.	2003;85:3319-3328.	
	
53.	 William’s	 Elong	 Edimo,	 Ana	 Raquel	 Ramos,	 Somadri	 Ghosh,	 Jean-Marie	
Vanderwinden,	Christophe	Erneux.	The	SHIP2	interactor	Myo1c	is	required	for	cell	
 64 











Growth	 Factor	 Receptor	 in	 Cancer	Metastasis	 and	Microenvironment.	 Hindawi	
Publishing	 Corporation	BioMed	Research	 International	 Volume	2013,	Article	 ID	
546318.10.1155/2013/546318.	
	
57.	 Nicola	 Normanno	 Antonella	 De	 Luca,	 Caterina	 Bianco,	 Luigi	 Strizzi,	 Mario	






























ER-alpha	 mutation	 Y537S	 confers	 Tamoxifen-resistance	 via	 enhanced	







67.	 Ernestina	 Marianna	 De	 Francesco,	 Gloria	 Bonuccelli,	 Marcello	 Maggiolini,	
Federica	 Sotgia	 and	Michael	 P.	 Lisanti.	 Vitamin	 C	 and	Doxycycline:	 A	 synthetic	




Tea	 Fevr,	 Laura	 Clark,	 Nora	 Bayani,	 Jean-Philippe	 Coppe1	 Frances	 Tong,	 Terry	
Speed,	Paul	T.	Spellman,	Sandy	DeVries,	Anna	Lapuk,	Nick	J.	Wang,	Wen-Lin	Kuo,	
Jackie	L.	Stilwell,	Daniel	Pinkel,	Donna	G.	Albertson,	Frederic	M.	Waldma,	Frank	












71.	 Andrew	 Paul	 Trotta,	 and	 Jerry	 Edward	 Chipuk.	 Mitochondrial	 Dynamics	 As	
Regulators	Of	Cancer	Biology.	Cell	Mol	Life	Sci.	2017.10.1007/s00018-016-2451-3.	
	
72.	 Matthew	 R.	 Zanotellia,	 Zachary	 E.	 Goldblatta,	 Joseph	 P.	 Millera,	 Francois	
Bordeleaub,	Jiahe	Lia,	Jacob	A.	VanderBurgha,	Marsha	C.	Lampia,	Michael	R.	Kinga	
and	Cynthia	A.	Reinhart-King.	Regulation	of	ATP	utilization	during	metastatic	cell	
migration	 by	 collagen	 architecture.	 MBoC	 (http://www	
.molbiolcell.org/cgi/doi/10.1091/mbc.E17-01-0041).	
	
73.	 Vi	 Ley	 Chin,	 Chooi	 Ling	 Lim.	 Epithelial-mesenchymal	 plasticity—engaging	
















77.	 Pelin	 Yaşar,	 Gamze	 Ayaz,	 Sırma	 Damla	 User,	 Gizem	 Güpür,	 Mesut	 Muyan.	



















82.	 Mark	 A.	 Eckert	 and	 Jing	 Yang.	 Targeting	 invadopodia	 to	 block	 breast	 cancer	
metastasis.	Oncotarget,	2011.	
	
83.	 William’s	 Elong	 Edimo,	 Ana	 Raquel	 Ramos,	 Somadri	 Ghosh,	 Jean-Marie	
Vanderwinden,	Christophe	Erneux.	The	SHIP2	interactor	Myo1c	is	required	for	cell	












consequencesand	 perspectivesa.	 Elsevier,	 EUROPEAN	 JOURNAL	 OF	 CANCER	 46	
(2010)	1198	–	1203.	
	
87.	 Matthew	 R.	 Zanotellia,	 Zachary	 E.	 Goldblatta,	 Joseph	 P.	 Millera,	 Francois	
Bordeleaub,	 Jiahe	 Lia,	 Jacob	 A.	 VanderBurgha,	 Marsha	 C.	 Lampia,	 Michael	 R.	












First of all, I would like to express my gratitude to all the Laboratory of 
Molecular Immunology and Oncology (MIaO Lab, University of Genoa) 
members and to my supervisor Fabio Ghiotto for their motivation, advises and 
guidance.  
 
In particular, a very special gratitude goes to Claudya Tenca and Elenina, 
their helpful, support and suggestions were very precious to me. They were 
not just colleagues, they were more. They were friends, and friends are 
essential. Among this I would like to thank Grazia Bellese, a cigarette with a 
good company can make easier everything, also work times. 
 
Many thanks to the Biochemistry Lab (University of Genoa), specially to 
Elena Laugeri for her helpful, supporting and wonderful times together. 
 
I would also like to acknowledge Michael P. Lisanti and Federica Sotgia 
(University of Salford) for giving me this great possibility to have a wonderful 
experience, for their valuable advises, patience and knowledge.  
 
Very special gratitude goes to Gloria Bonuccelli and to all the fantastic 
people of the Translational Medicine Lab: Rumana, Marco, Bela, and John.  
 
To Fanni, for all the food we shared together. Isn’t this friendship? 
 
To Ernestina and Alessandra, I wish we could work together again. 
 
In particular, to Sonia, Marta and Camillo for our good times and 
adventures we shared. 
 
Sincere thank goes to my friends, that are my family. To Annalinda, Camilla 
and Andrea. With all my love, I thank you. To the little Tommaso, I wish all my 
best to you. 
 
To Luisa, you got the best laugh I’ve ever heard. 
 
To Matelda, that every time reminds me to don’t stop to believe in love. 
 
Particularly thank goes to Alessia, Francesca and Emanuele for all your 
suggestions. 
 




Heartfelt thanks go to Margherita and Francesca, you helped me, always. 
I wish I could do the same for you. 
 
A special thank goes to Raffa, you taught me that happiness can be found 
in simplicity as a homemade cake shared with all your little women. I wish I 
could be like you one day. 
 
To Lorella Gasparini, my marvellous secondary school teacher, for all her 
support. 
 
To my fool friend Silvietta, you are amazing. I enjoyed every time I spent 
with you. 
 
To Dott.ssa Fabrizia Fiandesio, thank you to brought me to discover the 
world and myself. 
 
To my parents, and my family. To Eleonora for all her support. 
 
Finally, cause the very essential things need to tell at the end, I would like 
to say thank with all my heart to Paolo Scartezzini. Thanks to yours advises 
and immense knowledge. You taught me everything, you believed me, you 
supported me and you encouraged me. As a grandfather does, you’ve never 







Manchester (UK) 14.11.19, 
 
Filippo 
